Centauri Therapeutics Limited (‘Centauri’), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced it has secured £6 M from AMR Action Fund, extending the Company’s Series A round to £30 M.
Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.
Subscribe To Us
By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy
© 2026 Diabetes Prevention Awareness Center.